<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="43652">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02033525</url>
  </required_header>
  <id_info>
    <org_study_id>XCEL-MEN-01</org_study_id>
    <secondary_id>2011-006270-13</secondary_id>
    <nct_id>NCT02033525</nct_id>
  </id_info>
  <brief_title>Mesenchymal Stromal Cells for Degenerative Meniscus Injury</brief_title>
  <official_title>A Phase I-IIa Safety and Efficacy Pilot Clinical Trial of Intraarticular Administration of Autologous Mesenchymal Cells for Meniscus Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Banc de Sang i Teixits</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ICATME-Hospital Quiron Dexeus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ministerio de Sanidad, Servicios Sociales e Igualdad</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Banc de Sang i Teixits</source>
  <oversight_info>
    <authority>Spain: Spanish Agency of Medicines</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present proposal has the objective to assess whether the addition of autologous ex vivo
      expanded mesenchymal stromal cells (XCEL-M-ALPHA) to the conventional meniscal injury
      rehabilitation program is contributing in creating the proper healing environment for the
      meniscus repair. For this purpose, 20 patients will be randomized (10 per group) to one of
      the two treatment arms (rehabilitation + xcel-m-alpha or rehabilitation alone) . The
      conduction of this clinical trial will, in addition of having the aim of improving the
      patient's quality of life, contribute to consolidate an emerging new type of therapy which
      is still under development.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, unicentric, randomized, open-label, single-dose, two-arm, blinded
      assessor pilot study in which 20 patients with degenerative meniscus injury grade 3 (Crues
      et al.) will enter the study with the primary objective of assessing the efficacy of the
      treatment by VAS of pain at 12 month. Secondary objectives are to evaluate the safety and
      efficacy through imaging procedures and clinical questionnaires (IKDC, KOOS, Lysholm and
      SF-36.

      Patients will be randomized to one of the two treatment arms (XCEL-M-ALPHA and standard
      rehabilitation program or standard rehabilitation program alone). Thereafter, patients will
      be followed for 12 months.

      Imaging assessment will be performed by an independent blinded radiologist.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>VAS for pain</measure>
    <time_frame>12 month</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Visual analogue scale (VAS) for pain at 12 month follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>12 month</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Safety will be assessed by collecting adverse events, physical exam, laboratory tests, and vital signs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy by MRI</measure>
    <time_frame>6 and 12 month</time_frame>
    <safety_issue>No</safety_issue>
    <description>Efficacy will be assessed by qualitative and quantitative changes of the meniscus and articular cartilage by imaging procedures (MRI) at 6 and 12 month follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS for pain</measure>
    <time_frame>1, 3 and 6 month</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Visual analogue scale (VAS) for pain at 1, 3 and 6 month follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy by clinical questionnaires</measure>
    <time_frame>3, 6 and 12 month</time_frame>
    <safety_issue>No</safety_issue>
    <description>IKDC, KOOS and Lysholm functionality test and SF-36 quality of life at 3, 6 and 12 month follow-up</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Chronic Meniscal Injury</condition>
  <arm_group>
    <arm_group_label>XCEL-M-ALPHA and standard rehabilitation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intraarticular administration of XCEL-M-ALPHA followed by standard rehabilitation program</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard rehabilitation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard rehabilitation program</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XCEL-M-ALPHA and standard rehabilitation</intervention_name>
    <description>Intraarticular infusion of autologous bone marrow derived ex vivo expanded mesenchymal stromal cells</description>
    <arm_group_label>XCEL-M-ALPHA and standard rehabilitation</arm_group_label>
    <other_name>XCEL-M-ALPHA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Rehabilitation</intervention_name>
    <description>Standard rehabilitation program</description>
    <arm_group_label>standard rehabilitation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient between 40 and 60 years of age

          -  Degenerative meniscus injury grade 3 (Crues et al.)

          -  Indication of conservative treatment

          -  Normal alignment of the knee (between 3º varus and 10 º valgus)

          -  Patient is able to follow a rehabilitation program

          -  Informed consent given by the patient in writing

          -  Patient is able to understand the trial.

        Exclusion Criteria:

          -  Traumatic meniscus injury

          -  Surgical intervention to the affected knee

          -  Local or systemic infection

          -  Intraarticular treatment of the affected knee with steroids or hyaluronic acid within
             the past 3 months

          -  Significant abnormal laboratory tests that contraindicates participation in the
             trial.

          -  Pregnant women or intend to become pregnant or breast-feeding

          -  Neoplastic process within the previous 5 years or without complete remission.

          -  The patient is wearing a pacemaker, allergy to contrast, severe renal insufficiency
             or any other condition that contraindicates the magnetic resonance using contrast.

          -  Other pathologic conditions or circumstances that difficult participation in the
             study according to medical criteria

          -  Legally dependant patient.

          -  The patient does not accept to be followed-up for a period that could exceed the
             clinical trial length
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>çjoan Carles Monllau, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ICATME-Hospital Quiron Dexeus</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ruth Coll, MD</last_name>
    <phone>+34 935573500</phone>
    <phone_ext>6707</phone_ext>
    <email>rucoll@bst.cat</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joan Garcia, MD, PhD</last_name>
    <phone>+34 935573500</phone>
    <phone_ext>6700</phone_ext>
    <email>joangarcia@bst.cat</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ICATME-Hospital Quiron Dexeus</name>
      <address>
        <city>Barcelona</city>
        <zip>08028</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>rucoll@bst.cat</email>
    </contact>
    <investigator>
      <last_name>Joan Carles Monllau, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marc Tey, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.bancsang.net/en/index.html</url>
    <description>Blood and tissue bank of Catalonia</description>
  </link>
  <link>
    <url>http://www.icatme.com/</url>
    <description>Fundación ICATME (Spanish only)</description>
  </link>
  <link>
    <url>http://www.msssi.gob.es/</url>
    <description>Spanish Ministry of Healthcare</description>
  </link>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 9, 2014</lastchanged_date>
  <firstreceived_date>January 8, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Meniscal Injury</keyword>
  <keyword>Degenerative meniscus</keyword>
  <keyword>Meniscus injury</keyword>
  <keyword>Meniscal injury</keyword>
  <keyword>Mesenchymal stromal cells</keyword>
  <keyword>Mesenchymal stem cells</keyword>
  <keyword>Advanced Therapy</keyword>
  <keyword>Bone marrow</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
